8-K: Indaptus Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Listing

Indaptus Therapeutics, Inc. has announced the effectiveness of a 1-for-28 reverse stock split of its common stock, primarily aimed at regaining compliance with Nasdaq's continued listing requirements and attracting institutional investors.

Summary

• Indaptus Therapeutics, Inc. (Nasdaq: INDP) has completed a 1-for-28 reverse stock split of its common stock, effective after trading closed on June 26, 2025.
• The company's common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the same symbol INDP, starting June 27, 2025.
• This action was approved by stockholders at the Annual Meeting on June 10, 2025, with the Board of Directors determining the 1-for-28 ratio within the previously approved range of 1-for-5 to 1-for-28.
• The primary objectives of the reverse stock split are to increase the per share price and bid price of the common stock to regain compliance with Nasdaq's continued listing requirements and to make the stock more attractive to certain institutional investors.
• Every 28 shares of outstanding common stock were automatically converted into one share, without changing the par value per share.
• Proportionate adjustments were made to the exercise price and number of shares issuable for all outstanding options and warrants.
• No fractional shares were issued; instead, stockholders entitled to fractional shares will receive a cash payment based on the closing price on June 26, 2025.
• The number of authorized shares remains unchanged, but the number of outstanding shares will be reduced from approximately 16 million to approximately 572 thousand.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the reverse stock split addresses a critical compliance issue (Nasdaq listing), which is a positive step to avoid delisting, the underlying reason for needing such a split (a very low stock price) indicates significant challenges. The document also highlights substantial risks, including the need for additional capital and uncertainties in clinical development, which temper any positive outlook from the compliance action.

Positives

• The reverse stock split is intended to help the company regain compliance with Nasdaq's continued listing requirements, preventing potential delisting.
• Increasing the per share price may make the common stock more attractive to certain institutional investors, potentially broadening the investor base.

Negatives

• A reverse stock split often indicates a low stock price, which can be perceived negatively by the market and existing shareholders.
• The significant reduction in outstanding shares from approximately 16 million to 572 thousand could lead to reduced liquidity for individual investors.

Risks

• The company has a limited operating history.
• There are conditions and events that raise substantial doubt regarding the company's ability to continue as a going concern.
• The company needs to raise additional capital due to a lack of current cash flow.
• Clinical and preclinical development is a lengthy, expensive process with an uncertain outcome.
• The company incurs significant research and development and other operating expenses, making profitability difficult to attain.
• The company pursues a limited number of research programs, product candidates, and specific indications, potentially missing more profitable opportunities.
• Ability to obtain and maintain regulatory approval for any product candidate is uncertain.
• Market acceptance of product candidates is not guaranteed.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing poses risks.
• Ability to successfully commercialize Decoy20 or any future product candidates is uncertain.
• Ability to obtain or maintain coverage and adequate reimbursement for products is a concern.
• Impact of legislation and healthcare reform measures on marketing approval and commercialization.
• Competitors' product candidates may be approved faster, marketed more effectively, and better tolerated.
• Ability to adequately protect proprietary or licensed technology in the marketplace.
• Impact of, and costs of complying with, healthcare laws and regulations, and potential non-compliance.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies.
• Unfavorable global economic conditions.

Future Outlook

The company's forward-looking statements primarily focus on its ability to maintain the listing of its common stock on Nasdaq following the reverse stock split. It also acknowledges the inherent risks and uncertainties in its clinical and preclinical development, the need for additional capital, and the challenges of attaining profitability.

Management Comments

• The Board of Directors approved a one-for-twenty eight (1-for-28) reverse stock split of its common stock that became effective after trading closed on June 26, 2025.
• The reverse stock split aims to increase the per share price and bid price of the Company's common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.

Industry Context

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections. The reverse stock split is a corporate action often undertaken by smaller biotechnology companies to meet exchange listing requirements and improve stock attractiveness, particularly when their stock price has fallen significantly.

Corporate Governance

Stakeholder Impact

• Shareholders: Their number of shares will be reduced by a 1-for-28 ratio, and they will receive cash in lieu of any fractional shares. The per-share price is expected to increase.
• Potential Institutional Investors: The increased per-share price aims to make the stock more attractive to these investors, potentially broadening the company's investor base.
• Nasdaq: The action is intended to regain compliance with Nasdaq's continued listing requirements.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on June 27, 2025.
• VStock Transfer, LLC, the company's transfer agent, will send instructions to stockholders holding physical stock certificates for exchanging them for new certificates representing the post-split number of shares.

Key Dates

Keywords

Reverse Stock Split, Nasdaq Compliance, Biotechnology, Cancer Treatment, Viral Infection Treatment, INDP, SEC Filing, Corporate Action, Stockholders Meeting